STX fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Shield Therapeutics Plc is a commercial stage specialty pharmaceutical company, which engages in addressing iron deficiency with its lead product Accrufer. It operates the Feraccru and PT20 segments. The Feraccru segment refers to the development and commercialization of this product. The PT20 segment related to the development of its secondary asset. The company was founded by Carl Sterritt and Christian Schweiger in 2008 and is headquartered in Gateshead Quays, the United Kingdom.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
STX does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company